Handelsavisen
prelaunch
Companies Healthcare GYRE.O
GY
GYRE.O NASDAQ Biotechnology

Gyre.O

$6,11
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
557,9M USD
P/E
EV / Rev
4,4x
Div yield
Op margin
-0,1 %
ROE
-6,0 %
Net margin
-5,4 %
Debt / equity
Beta
52w range
Volume
Day range
Prev close
$5,99
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Gyre Therapeutics Inc operates as a biotechnology company within the Health Care sector, generating revenue through its disclosed business activities.

Business. Gyre Therapeutics Inc operates as a biotechnology company within the Health Care sector, generating revenue through its disclosed business activities.

Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
BUY3 analysts
3 buy0 hold0 sell
Avg 12m price target18,67

Analyst recommendations

3 analysts · consensus Buy
Buy3
Hold0
Sell0
12-month price target
18,67
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
3 analysts · indicative
Ownership
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability
-6,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning GYRE.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to GYRE.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Gyre Therapeutics Inc operates as a biotechnology company within the Health Care sector, generating revenue through its disclosed business activities.

    Classification85 %
    SectorHealth Care
    Industry groupBiotechnology
    AI synthesis
    GENERATED

    The company maintains a conservative capital structure with zero debt-to-equity and total liabilities of $23.85 million against total equity of $106.03 million. Liquidity is supported by cash and equivalents of $37.07 million, which exceeds total liabilities, resulting in a low liquidity risk assessment. The balance sheet reflects a net asset position that underpins the current valuation metrics.

    Profitability metrics show a net income of $9.88 million on revenue of $116.59 million, indicating a positive operating margin. However, return on equity is reported as -0.06 and return on assets as -0.0383, suggesting discrepancies between accounting net income and the computed return ratios or the inclusion of non-cash items in the equity base. The negative EV/EBITDA of -3616.32 indicates that EBITDA is likely negative or near zero, contrasting with the positive operating income of $11.49 million.

    Segment and geographic data are not provided in the available source documents, preventing an analysis of revenue concentration or regional exposure. The company's revenue mix remains undifferentiated in the current dataset.

    Historical period data for revenue and net income trends is absent, limiting the ability to assess growth trajectory or consistency over time. The current snapshot provides a single-period view of financial performance.

    Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. The shares outstanding basic and diluted are identical at 91.31 million, suggesting no significant in-the-money options or convertible securities impacting dilution at the current market price.

    Recent observations include analyst estimates with a mean price target of $18.67 and a mean recommendation of 1.67, indicating strong buy sentiment. News events reflect internal reconciler activities for analysis job admission rather than external corporate actions.

    Key takeaways
    • The company holds a strong liquidity position with $37.07 million in cash and zero debt.
    • Analyst sentiment is bullish with a mean price target of $18.67, significantly above the current market price of $5.99.
    • Dilution risk is low with no difference between basic and diluted shares outstanding.
    • Profitability signals are mixed with positive net income but negative return on equity and assets.
    • EV/EBITDA is negative, suggesting operational cash flow challenges despite positive operating income.
    • margin_outlook_rationale: Margins appear positive based on operating income but are obscured by negative return ratios.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-05-07
    Q1 2026 · Quarter highlights
    Open report →

    Revenue $22.5M, +2,1% YoY; Operating income −511,6% YoY.

    Revenue$22.5M+2,1 % YoY
    Operating income-$9.4M−511,6 % YoY
    Net income-$8.7M−422,1 % YoY
    Free cash flow-$9.4M−371,7 % YoY
    EPS
    Operating cash flow$3.2M+2 565,1 % YoY
    Financials
    Income statement
    Revenue$22.5M
    Gross profit$21.3M
    Operating income-$9.4M
    Net income-$8.7M
    Margins
    Gross margin94.6%
    Operating margin-41.5%
    Net margin-38.6%
    FCF margin-41.6%
    Balance sheet
    Total assets$162.0M
    Total liabilities$60.7M
    Total equity$101.3M
    Cash & equivalents$37.5M
    Long-term debt$0.00
    Cash flow
    Operating cash flow$3.2M
    CapEx-$183.0k
    Free cash flow-$9.4M
    SBC
    P&L flow · revenue → net income
    Revenue $22.5MOperating costs $31.9MNet income $8.7M
    Highlights
    • Revenue $22.5M, +2,1% YoY
    • Operating income −511,6% YoY
    • Net income −422,1% YoY
    • Free cash flow −371,7% YoY
    • Net margin -38.6%

    Valuation TTM

    Market price
    $6,11
    Market cap
    $547.0M
    Enterprise value
    $509.9M
    P/E
    Non-GAAP P/E
    EV / Revenue
    4.4x
    EV / Op income
    EV / OCF
    504.9x
    P / B
    3.8x
    P / Tangible book
    3.8x
    Tangible book
    $142.3M
    Net cash
    $37.1M
    Current ratio
    Debt / equity
    ROA
    -3.8%
    ROE
    -6.0%
    Cash conversion
    -16.0%
    CapEx / revenue
    -1.6%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,45
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    3
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-07-29 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,45
    Revenueno estimateno estimate102,3M USD
    Operating incomeno estimateno estimate-19,0M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution3 analysts
    Strong buy1
    Buy2
    Hold0
    Sell0
    Strong sell0
    12-month price target$18,67 · Median $18,00
    Low $18,00High $20,00
    Operating income · consensus-19,0M USD
    EPS surprise
    +140,0 %
    reported vs consensus · beat
    Revenue surprise
    +14,0 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$18,00
    Mean$18,67
    Median$18,00
    High$20,00
    Spot$6,11
    +205.5 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-0,1 %Above P75
    Net Margin-5,4 %Above median
    ROE-6,0 %Above P75
    Capex / Rev-1,6 %Below median
    D/E0,00Above median
    Cash Conv-0,16Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 13 764 142 sh16 exercises · 17 grants12 insiders
    • Ye WeiguoChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 3 000 @ $0,75exercise · 2026-06-18
    • Ye WeiguoChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 2 800 @ $0,75exercise · 2026-06-11
    • Parry RenateDirector · Stock Option (Right to Buy) → Common StockAcquired 40 000 @ $5,95grant · 2026-06-10
    • Carmichael GordonDirector · Stock Option (Right to Buy) → Common StockAcquired 40 000 @ $5,95grant · 2026-06-10
    • Epstein David M.Director · Stock Option (Right to Buy) → Common StockAcquired 40 000 @ $5,95grant · 2026-06-10
    • Weng DanDirector · Stock Option (Right to Buy) → Common StockAcquired 40 000 @ $5,95grant · 2026-06-10
    • Nussbaum Rodney LDirector · Stock Option (Right to Buy) → Common StockAcquired 40 000 @ $5,95grant · 2026-06-10
    • Zhang PingDirector · Stock Option (Right to Buy) → Common StockAcquired 40 000 @ $5,95grant · 2026-06-10
    • Ye WeiguoChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 5 000 @ $0,75exercise · 2026-06-10
    • Ye WeiguoChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 6 418 @ $0,75exercise · 2026-06-10
    • Ye WeiguoChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 14 500 @ $0,75exercise · 2026-06-09
    • Ye WeiguoChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 3 000 @ $0,75exercise · 2026-06-09
    • Bergmann Joshua BenjaminGC and Corporate Secretary · Stock Option (Right to Buy) → Common StockAcquired 50 000 @ $6,05grant · 2026-06-08
    • Luo YingDirector, Chief Executive Officer · Stock Option (Right to Buy) → Common StockAcquired 120 000 @ $6,05grant · 2026-06-08
    • Ye WeiguoChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 15 401 @ $0,75exercise · 2026-06-05
    • Ye WeiguoChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 19 575 @ $0,75exercise · 2026-06-04
    • Ye WeiguoChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 4 000 @ $0,75exercise · 2026-05-26
    • Ye WeiguoChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 3 500 @ $0,75exercise · 2026-05-22
    • Ye WeiguoChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 12 820 @ $0,75exercise · 2026-05-21
    • Ye WeiguoChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 9 400 @ $0,75exercise · 2026-05-20
    • Ye WeiguoChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 9 120 @ $0,75exercise · 2026-05-19
    • Ye WeiguoChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 200 @ $0,75exercise · 2026-05-18
    • Ye WeiguoChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 13 100 @ $0,75exercise · 2026-05-15
    • Ye WeiguoChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 15 580 @ $0,75exercise · 2026-05-14
    • Zhang PingDirector · Stock Option (Right to Buy) → Common StockDisposed 250 000 @ $10,18disposition · 2026-05-14

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Reference data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Ev To Revenue
      enterprise_value / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • Gyre Therapeutics, Inc. Market data — financials · 2026-07-29
    • reconciler_enqueue (reconciler) on GYRE.O · 2026-07-29
    • Gyre Therapeutics Inc Market data — analyst estimates · 2026-07-29
    • Gyre Therapeutics Inc Market data — ESG · 2026-07-29

    Ownership & reference

    Top holders

    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$3M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$6M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$8M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$2M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Leadership

    • Ying LuoPresident, Chief Executive Officer, Director

    Insider activity

    Net selling0 buys · 18 sellsnet -$953K2 insiders · last 365d
    • Ye WeiguoChief Operating Officer · Common StockSold 3 000 @ $6,35$19K · 2026-06-18
    • Ye WeiguoChief Operating Officer · Common StockOther 3 000 @ $0,75$2K · 2026-06-18
    • Ye WeiguoChief Operating Officer · Common StockOther 2 800 @ $0,75$2K · 2026-06-11
    • Ye WeiguoChief Operating Officer · Common StockSold 2 800 @ $6,17$17K · 2026-06-11
    • Ye WeiguoChief Operating Officer · Common StockOther 5 000 @ $0,75$4K · 2026-06-10
    • Ye WeiguoChief Operating Officer · Common StockSold 6 418 @ $6,21$40K · 2026-06-10
    • Ye WeiguoChief Operating Officer · Common StockSold 5 000 @ $6,24$31K · 2026-06-10
    • Ye WeiguoChief Operating Officer · Common StockOther 6 418 @ $0,75$5K · 2026-06-10
    • Ye WeiguoChief Operating Officer · Common StockOther 3 000 @ $0,75$2K · 2026-06-09
    • Ye WeiguoChief Operating Officer · Common StockSold 3 000 @ $6,15$18K · 2026-06-09
    • Ye WeiguoChief Operating Officer · Common StockOther 14 500 @ $0,75$11K · 2026-06-09
    • Ye WeiguoChief Operating Officer · Common StockSold 14 500 @ $6,14$89K · 2026-06-09
    • Ye WeiguoChief Operating Officer · Common StockOther 15 401 @ $0,75$12K · 2026-06-05
    • Ye WeiguoChief Operating Officer · Common StockSold 15 401 @ $6,40$99K · 2026-06-05
    • Ye WeiguoChief Operating Officer · Common StockOther 19 575 @ $0,75$15K · 2026-06-04
    • Ye WeiguoChief Operating Officer · Common StockSold 19 575 @ $6,13$120K · 2026-06-04
    • Ye WeiguoChief Operating Officer · Common StockOther 4 000 @ $0,75$3K · 2026-05-26
    • Ye WeiguoChief Operating Officer · Common StockSold 4 000 @ $6,10$24K · 2026-05-26
    • Ye WeiguoChief Operating Officer · Common StockSold 3 500 @ $6,08$21K · 2026-05-22
    • Ye WeiguoChief Operating Officer · Common StockOther 3 500 @ $0,75$3K · 2026-05-22
    • Ye WeiguoChief Operating Officer · Common StockSold 12 820 @ $6,15$79K · 2026-05-21
    • Ye WeiguoChief Operating Officer · Common StockOther 12 820 @ $0,75$10K · 2026-05-21
    • Ye WeiguoChief Operating Officer · Common StockOther 9 400 @ $0,75$7K · 2026-05-20
    • Ye WeiguoChief Operating Officer · Common StockSold 9 400 @ $6,15$58K · 2026-05-20
    • Ye WeiguoChief Operating Officer · Common StockOther 9 120 @ $0,75$7K · 2026-05-19

    Short positioning

    2.0Mshares short+11.9% vs prior
    24.18days to cover
    68.0%short of daily vol
    8.5Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    GYRE.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • Capex (annual): USD 1.19MUnknown
    • Total operating expenses (annual): USD 105.1MUnknown
    • EPS (diluted) (annual): USD-PER-SHARES 0Unknown
    • Cost of revenue (annual): USD 5.42MUnknown
    • EPS (basic) (annual): USD-PER-SHARES 0Unknown
    • R&D expense (annual): USD 13.7MUnknown
    • Pre-tax income (annual): USD 14.44MUnknown
    • Net income (annual): USD 9.88MUnknown
    • Operating cash flow (annual): USD 1.01MUnknown
    • Revenue (annual): USD 116.59MUnknown
    • Total assets (annual): USD 166.13MUnknown
    • Current liabilities (annual): USD 18.29MUnknown
    • Total liabilities (annual): USD 23.85MUnknown
    • Current assets (annual): USD 102.37MUnknown
    • Operating income (annual): USD 11.49MUnknown
    • Cash & equivalents (annual): USD 37.07MUnknown
    • Shares outstanding (annual): 91.31MUnknown
    • Shareholders' equity (annual): USD 106.03MUnknown
    • Revenue (annual): USD 105.76MUnknown
    • Cash & equivalents (annual): USD 11.81MUnknown
    • R&D expense (annual): USD 12.02MUnknown
    • Capex (annual): USD 2.31MUnknown
    • Operating cash flow (annual): USD -3.64MUnknown
    • Current assets (annual): USD 64.79MUnknown
    Showing 24 of 35 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-18 00:00 UTCINSIDER26 insider transactions — 2026-06 · net sell $381k 10 derivative
    2026-06-18 00:00 UTCINSIDER26 insider transactions — 2026-06 · net sell $381k 10 derivative
    2026-06-18INSIDERYe Weiguo sold 3.0k sh — Chief Operating Officer ~$19k
    2026-06-18INSIDERYe Weiguo transacted 3.0k sh — Chief Operating Officer ~$2k
    2026-06-18INSIDERYe Weiguo disposed of 3.0k sh Stock Option (Right to Buy) — Chief Operating Officer
    2026-06-16FILING8-K filing →
    2026-06-11INSIDERYe Weiguo sold 2.8k sh — Chief Operating Officer ~$17k
    2026-06-11INSIDERYe Weiguo transacted 2.8k sh — Chief Operating Officer ~$2k
    2026-06-11INSIDERYe Weiguo disposed of 2.8k sh Stock Option (Right to Buy) — Chief Operating Officer
    2026-06-10INSIDERYe Weiguo sold 6.4k sh — Chief Operating Officer ~$40k
    2026-06-10INSIDERYe Weiguo transacted 5.0k sh — Chief Operating Officer ~$4k
    2026-06-10INSIDERYe Weiguo sold 5.0k sh — Chief Operating Officer ~$31k
    2026-06-10INSIDERYe Weiguo transacted 6.4k sh — Chief Operating Officer ~$5k
    2026-06-10INSIDERParry Renate acquired 40.0k sh Stock Option (Right to Buy) — Director
    2026-06-10INSIDERNussbaum Rodney L acquired 40.0k sh Stock Option (Right to Buy) — Director
    2026-06-10INSIDERWeng Dan acquired 40.0k sh Stock Option (Right to Buy) — Director
    2026-06-10INSIDEREpstein David M. acquired 40.0k sh Stock Option (Right to Buy) — Director
    2026-06-10INSIDERCarmichael Gordon acquired 40.0k sh Stock Option (Right to Buy) — Director
    2026-06-10INSIDERZhang Ping acquired 40.0k sh Stock Option (Right to Buy) — Director
    2026-06-10INSIDERYe Weiguo disposed of 6.4k sh Stock Option (Right to Buy) — Chief Operating Officer
    2026-06-10INSIDERYe Weiguo disposed of 5.0k sh Stock Option (Right to Buy) — Chief Operating Officer
    2026-06-09INSIDERYe Weiguo transacted 3.0k sh — Chief Operating Officer ~$2k
    2026-06-09INSIDERYe Weiguo transacted 14.5k sh — Chief Operating Officer ~$11k
    2026-06-09INSIDERYe Weiguo sold 14.5k sh — Chief Operating Officer ~$89k
    2026-06-09INSIDERYe Weiguo sold 3.0k sh — Chief Operating Officer ~$18k
    2026-06-09INSIDERYe Weiguo disposed of 14.5k sh Stock Option (Right to Buy) — Chief Operating Officer
    2026-06-09INSIDERYe Weiguo disposed of 3.0k sh Stock Option (Right to Buy) — Chief Operating Officer
    2026-06-08INSIDERLuo Ying acquired 120.0k sh Stock Option (Right to Buy) — Director, Chief Executive Officer
    2026-06-08INSIDERBergmann Joshua Benjamin acquired 50.0k sh Stock Option (Right to Buy) — GC and Corporate Secretary
    2026-06-05INSIDERYe Weiguo transacted 15.4k sh — Chief Operating Officer ~$12k
    2026-06-05INSIDERYe Weiguo sold 15.4k sh — Chief Operating Officer ~$99k
    2026-06-05INSIDERYe Weiguo disposed of 15.4k sh Stock Option (Right to Buy) — Chief Operating Officer
    2026-06-04INSIDERYe Weiguo sold 19.6k sh — Chief Operating Officer ~$120k
    2026-06-04INSIDERYe Weiguo transacted 19.6k sh — Chief Operating Officer ~$15k
    2026-06-04INSIDERYe Weiguo disposed of 19.6k sh Stock Option (Right to Buy) — Chief Operating Officer
    2026-06-02FILING8-K filing →
    2026-05-26 00:00 UTCINSIDER34 insider transactions — 2026-05 · net sell $469k 16 derivative
    2026-05-26 00:00 UTCINSIDER34 insider transactions — 2026-05 · net sell $469k 16 derivative
    2026-05-26INSIDERYe Weiguo sold 4.0k sh — Chief Operating Officer ~$24k
    Showing the 40 most recent of 72 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage